Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19.
Evan M BlochDaniele FocosiShmuel ShohamJonathon SenefeldAaron A R TobianLindsey R BadenPierre TiberghienDavid SullivanClaudia CohnVeronica DiovertiJeffrey P HendersonCynthia So-OsmanJustin E JuskewitchRaymund R RazonableMassimo FranchiniRuchika GoelBrenda J GrossmanArturo CasadevallMichael J JoynerRobin K AveryLiise-Anne PirofskiKelly GeboPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
COVID-19 convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immune compromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-titer SARS-CoV-2 antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- chronic kidney disease
- respiratory syndrome coronavirus
- gene expression
- primary care
- intensive care unit
- cardiac surgery
- dna methylation
- acute respiratory distress syndrome
- drug induced
- respiratory failure
- replacement therapy
- hepatitis b virus